• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于低遗传屏障方案的替代转换策略：如今临床医生有选择吗？

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

机构信息

Hospital Universitario Infanta Leonor, Madrid, Spain.

School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.

出版信息

Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):423-426. doi: 10.1007/s10096-018-3429-x. Epub 2018 Nov 15.

DOI:10.1007/s10096-018-3429-x
PMID:30443683
Abstract

Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.

摘要

临床医生有时会根据 RAL + ABC/3TC 或 RPV + ABC/3TC 等方案使用转换策略，以解决与传统推荐的一线治疗策略相关的耐受性或安全性问题。尽管这些方案的遗传屏障较低，但回顾性研究报告了它们的高安全性和疗效。

相似文献

1
Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?基于低遗传屏障方案的替代转换策略：如今临床医生有选择吗？
Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):423-426. doi: 10.1007/s10096-018-3429-x. Epub 2018 Nov 15.
2
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.在接受高效抗逆转录病毒治疗（HAART）且病毒学抑制的HIV感染患者中换用阿巴卡韦/拉米夫定（ABC/3TC）加rilpivirine（RPV）的疗效和安全性。
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):815-9. doi: 10.1007/s10096-016-2602-3. Epub 2016 Feb 15.
3
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.阿巴卡韦/拉米夫定联合雷特格韦用于有HIV-1感染治疗史和初治患者的疗效及安全性：一项观察性、回顾性、多中心研究
Int J STD AIDS. 2019 Apr;30(5):467-471. doi: 10.1177/0956462418817049. Epub 2019 Jan 10.
4
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全的治疗策略：SIMRIKI回顾性研究的48周结果
PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016.
5
Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.拉替拉韦与阿巴卡韦/拉米夫定用于日本初治和经治HIV感染患者：一项48周回顾性初步分析
Jpn J Infect Dis. 2016;69(1):33-8. doi: 10.7883/yoken.JJID.2014.236. Epub 2015 May 12.
6
Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.拉替拉韦与阿巴卡韦/拉米夫定或齐多夫定/拉米夫定治疗 HIV 感染韩国成年人的临床经验。
Jpn J Infect Dis. 2013;66(4):317-9. doi: 10.7883/yoken.66.317.
7
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.拉替拉韦加利伟/阿巴卡韦/拉米夫定治疗病毒学抑制的 HIV-1 感染者：KIRAL 研究的 48 周结果。
PLoS One. 2018 Jun 14;13(6):e0198768. doi: 10.1371/journal.pone.0198768. eCollection 2018.
8
Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.阿巴卡韦/拉米夫定联合rilpivirine作为初治HIV-1感染成人一线治疗方案的疗效和安全性。
AIDS Res Ther. 2020 May 21;17(1):23. doi: 10.1186/s12981-020-00272-5.
9
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.接受阿巴卡韦加拉米夫定和依非韦伦治疗的初治HIV感染患者的基因型耐药性
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):253-5. doi: 10.1097/QAI.0b013e318074efd1.
10
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.多替拉韦/阿巴卡韦/拉米夫定与当前抗逆转录病毒疗法用于病毒学抑制患者的比较（STRIIVING）：一项48周的随机、非劣效性、开放标签的IIIb期研究。
Antivir Ther. 2017;22(4):295-305. doi: 10.3851/IMP3166. Epub 2017 Apr 12.

本文引用的文献

1
Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity.对于出现替诺福韦相关肾毒性的HIV感染患者，改用阿巴卡韦与使用保留核苷的双药方案的比较。
HIV Med. 2018 Jun 22. doi: 10.1111/hiv.12630.
2
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.拉替拉韦加利伟/阿巴卡韦/拉米夫定治疗病毒学抑制的 HIV-1 感染者：KIRAL 研究的 48 周结果。
PLoS One. 2018 Jun 14;13(6):e0198768. doi: 10.1371/journal.pone.0198768. eCollection 2018.
3
The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
在HIV感染患者中，将蛋白酶抑制剂换用拉替拉韦对内皮功能的影响。
HIV Clin Trials. 2018 Apr;19(2):75-83. doi: 10.1080/15284336.2018.1455366.
4
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.利匹韦林联合阿巴卡韦和拉米夫定用于病毒载量不可测的HIV-1感染患者的长期疗效和安全性
PLoS One. 2018 Feb 16;13(2):e0191300. doi: 10.1371/journal.pone.0191300. eCollection 2018.
5
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.一项评估向感染HIV-1的患者改用拉替拉韦加阿巴卡韦/拉米夫定的观察性回顾性分析：ORASWIRAL研究
Infect Dis (Lond). 2018 Mar;50(3):220-222. doi: 10.1080/23744235.2017.1374552. Epub 2017 Sep 11.
6
Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?
.用于治疗艾滋病病毒的通用抗逆转录病毒药物：对西方国家来说是一个新挑战？
Int J Clin Pharmacol Ther. 2017 May;55(5):381-393. doi: 10.5414/CP202775.
7
Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.在病毒学抑制的人类免疫缺陷病毒感染患者中，从抗逆转录病毒药物替诺福韦酯/恩曲他滨转换为硫酸阿巴卡韦/拉米夫定后脂质浓度的评估。
Intern Med. 2016;55(23):3435-3440. doi: 10.2169/internalmedicine.55.7518. Epub 2016 Dec 1.
8
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全的治疗策略：SIMRIKI回顾性研究的48周结果
PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016.
9
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.阿巴卡韦/拉米夫定+利匹韦林方案治疗初治HIV-1感染患者的有效性和安全性
J Antimicrob Chemother. 2016 Dec;71(12):3510-3514. doi: 10.1093/jac/dkw347. Epub 2016 Sep 2.
10
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.在接受高效抗逆转录病毒治疗（HAART）且病毒学抑制的HIV感染患者中换用阿巴卡韦/拉米夫定（ABC/3TC）加rilpivirine（RPV）的疗效和安全性。
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):815-9. doi: 10.1007/s10096-016-2602-3. Epub 2016 Feb 15.